XPO1 is a new target of homoharringtonine (HHT): Making NPMc+ AML cells much more sensitive to HHT treatment
Open Access
- 16 July 2023
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 675, 155-161
Abstract
No abstract availableKeywords
Funding Information
- Dalian Medical University (dy2yhbrc202007)
- National Natural Science Foundation of China (82000201)
- Natural Science Foundation of Liaoning Province (2021-BS-203)
This publication has 17 references indexed in Scilit:
- When the good go bad: Mutant NPM1 in acute myeloid leukemiaBlood Reviews, 2018
- The role of targeted therapy in the management of patients with AMLBlood Advances, 2017
- Assessment of Minimal Residual Disease in Standard-Risk AMLNew England Journal of Medicine, 2016
- CRM1 Is a Cellular Target of Curcumin: New Insights for the Myriad of Biological Effects of an Ancient SpiceTraffic, 2013
- Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift AssayScience, 2013
- Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemiaBlood, 2012
- Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical featuresBlood, 2006
- Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)Blood, 2006
- Delocalization and Destabilization of the Arf Tumor Suppressor by the Leukemia-Associated NPM MutantCancer Research, 2006
- HomoharringtonineCancer, 2001